Abstract
60 intracranial tumors have been studied immunohistochemically to determine the proliferation rate by staining for the monoclonal antibody KI-67, which recognizes a nuclear antigen expressed by cells in proliferation. In gliomas a clear correlation of stained nuclei to the histologically determined degree of malignancy was found: slow growing astrocytomas and oligodendrogliomas had an average proliferation rate of 1%, more malignant forms of 7–10%. Glioblastomas were found to have a growth fraction of 15%. Metastases had an even higher rate of 20% proliferating cells. In meningiomas the proliferation rate was mainly about 1%, but in three cases it was between 5% and 7%. Whether this is indicative for a higher risk of tumor recurrence, remains to be correlated to the clinical course. Hemangiopericytomas had a proliferation rate of 9% and 16%, respectively, the latter recurring within four months. It may be concluded from the results of this study, that investigation of intracranial tumors with KI 67 may be of prognostic value and can possibly contribute to an individualized tumor therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adegbite, AB, MI Khan, KWE Paine, LK Tan: The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58 (1983) 51–56
Böker DK, H Meurer, F Gullotta: Recurring intracranial meningiomas. Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 29 (1985) 11–17
Burger PC, RT Vollmer: Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46 (1980) 1179–1186
Burger PC, T Shibata, P Kleihues: The use of the monoclonal antibody KI 67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10 (1986) 611–617
Crompton RM, PC Gautier-Smith: The prediction of recurrence in meningiomas. J Neurol Neurosurg Psychiat 33 (1970) 80–87
Gerdes, J, U Schwab, H Lemke, H Stein: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31 (1983) 13–20
Gerdes J, F Dallenbach, K Lennert: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody KI-67. Hematol Oncol 2 (1984) 365–371
Gerdes J, H Lemke, H Baisch, HH Wacker, U Schwab, H Stein: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody KI-67. J Immunol 133 (1984) 1710–1715
Giangaspero F, PC Burger: Correlations between cytologic composition and biologic behaviour in the glioblastoma multiforme. A postmortem study of 50 cases. Cancer 52 (1983) 2320–2333
Giangaspero F, C Doglioni, MT Rivano, S Pileri, J Gerdes, H Stein: Growth fraction in human brain tumors defined by the monoclonal antibody KI-67. Acta Neuropathol (Berl) 74 (1987) 179–182
Hoshino T, M Barker, CB Wilson, EB Boldrey, D Fewer: Cell kinetics of human gliomas. J Neurosurg 37 (1972) 15–26
Hoshino T, CB Wilson, ML Rosenblum, M Barker: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43 (1975) 127–135
Hoshino T, CB Wilson: Cell kinetic analysis of human malignant brain tumors (gliomas). Cancer 44 (1979) 956–962
Hoshino T, T Nagashima, JA Murovic, CB Wilson, MSB Edwards, PH Gutin, RL Davis, SJ DeArmond: In situ cell kinetics studies on human neuroectoderma tumors with bromodeoxyuridine labeling. J Neurosurg 64 (1986) 453–459
Johnson HA, WE Haymaker, JR Rubini, TM Fliedner, VP Bond, EP Cronkite, WL Hughes: A radioautographic study of a human glioblastoma multiforme after the in vivo uptake of tritiated thymidine. Cancer 13 (1960) 636–642
Kury G, HW Carter: Autoradiographic study of human nervous system tumors. Arch Path 80 (1965) 38–42
Lloyd RV, BS Wilson, J Varani, PK Gaur, S Moline, JG Makari: Immunocytochemical characterization of a monoclonal antibody that recognizes mitosing cells. Am J Pathol 121 (1985) 275–283
Malaise EP, N Chavaudra, M Tubiani: The relationship between growth rate, labelling index and histological type of human solid tumors. Europ J Cancer 9 (1973) 305–312
Melamed S, A Sahar, AJ Beller: The recurrence of intracranial meningiomas. Neurochirurgia 22 (1979) 47–51
Nagashima T, SJ DeArmond, J Murovic, T Hoshino: Immunocytochemical demonstration of Sphase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissues. Acta Neuropathol (Berl) 67 (1985) 155–159
Roggendorf W, T Schuster, J Peiffer: Proliferative potential of meningiomas determined with the monoclonal antibody KI-67. Acta Neuropathol (Berl) 73 (1987) 361–364
Sato Y, K Mukai, S Watanabe, M Goto, Y Shimosato: The AMeX method. A simplified technique if tissue processing and paraffin embedding with proved preservation of antigens for immunostaining. Am J Pathol 125 (1986) 431–435
Yamashita J, H Handa, K Iwaki, M Abe: Recurrence of intracranial meningiomas, with special reference to radiotherapy. Surg Neurol 14 (1980) 33–40
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Böker, DK., Stark, HJ. The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens. Neurosurg. Rev. 11, 267–272 (1988). https://doi.org/10.1007/BF01741421
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741421